[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100412414":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":31,"centralContacts":35,"locations":41,"responsibleParty":57,"collaborators":39,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":61,"sex":67,"minAge":68,"maxAge":39,"enrollmentInfo":69,"targetDuration":39,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":78,"overallStatus":43,"whyStopped":39,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Peking Union Medical College Hospital","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"10mg\u002FKg UDCA","EXPERIMENTAL","Patients will receive a reduced dosage of 10mg\u002FKg UDCA orally everyday.",[13],"Drug: ursodeoxycholic acid",{"label":15,"type":10,"description":16,"interventionNames":17},"5mg\u002FKg UDCA","Patients will receive a reduced dosage of 5mg\u002FKg UDCA orally everyday.",[13],{"label":19,"type":20,"description":21,"interventionNames":22},"standard 13-15mg\u002FKg UDCA","ACTIVE_COMPARATOR","Patients will receive standard dosage of 13-15mg\u002FKg UDCA everyday.",[13],[24],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"DRUG","ursodeoxycholic acid","The two experimental groups will receive reduced dosage of UDCA at 10mg\u002FKg and 5mg\u002FKg everyday respectively, while the control group will receive standard dosage of UDCA.The treatment duration will be at least one year.",[9,15,19],[30],"UDCA",[32],{"name":33,"affiliation":5,"role":34},"Li Wang","STUDY_DIRECTOR",[36],{"name":33,"role":37,"phone":38,"phoneExt":39,"email":40},"CONTACT","8613801175089",null,"wangli2221@sina.com",[42],{"facility":5,"status":43,"city":44,"state":39,"zip":39,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"RECRUITING","Beijing","China","CN",{"type":48,"coordinates":49},"Point",[50,51],116.39723,39.9075,{"lat":51,"lon":50},[54,55],{"name":33,"role":37,"phone":38,"phoneExt":39,"email":40},{"name":33,"role":56,"phone":39,"phoneExt":39,"email":39},"PRINCIPAL_INVESTIGATOR",{"type":58,"investigatorFullName":39,"investigatorTitle":39,"investigatorAffiliation":39,"oldNameTitle":39,"oldOrganization":39},"SPONSOR","100412414","phase-4-clinical-research-of-tapering-udca-in-pbc-patients-with-a-complete-response-100412414",false,"NCT04650243","Clinical Research of Tapering UDCA in PBC Patients With a Complete Response","Clinical Research of Tapering Ursodeoxycholic Acid in Primary Biliary Cholangitis Patients With A Complete Response","UDCA PBC","Inclusion Criteria:\n\n* Satisfied the diagnostic criteria of PBC by the AASLDin 2000;\n* Age≥18 years\n* Clinical stage 2 and 3 (i.e. abnormal liver function and symptomatic phase);\n* Patients with improved liver biochemical index( ALP and AST≤1.5× upper limit of normal, with a normal bilirubin level) after 6 to 12 months treatment of UDCA;\n* Informed consent obtained.\n\nExclusion Criteria:\n\n* Overlapped with other liver diseases (such as HBV, HCV, alcoholic cirrhosis, etc.) or serum ALT, AST more than 2 ULN;\n* Decompensation of liver function (Child grade B\u002FC);\n* Complicated with important organ failure (such as renal insufficiency), serious infection or other serious complications;\n* Pregnancy, preparation for pregnancy or pregnancy Lactation, psychiatric subjects, etc.;\n* Participating in other clinical trials or participated in other clinical trials in three months.","ALL","18 Years",{"count":70,"type":71},90,"ESTIMATED","INTERVENTIONAL",[74],"PHASE4","This study explores the feasibility of the reducing medication regimen for Ursodeoxycholic Acid(UDCA) in the treatment of primary biliary cholangitis. The participants will be distributed randomly into two experimental groups and one control group. The two experimental groups will receive reduced dosage of UDCA at different level, while the control group will receive standard dosage of UDCA. The effect of therapy will be evaluated every three months.",[77],"Primary Biliary Cholangitis",[26,79],"reducing medication regimen","2025-03-26",{"date":82,"type":83},"2025-04-01","ACTUAL",{"date":85,"type":83},"2020-01-21",{"date":87,"type":71},"2025-05",{"name":5,"class":6},1]